Live easier thanks
to innovative technology

When epilepsy patients do not or only partially respond to drug treatments, treatment with EASEE® can help with low-risk, supportive medical technology. EASEE® stimulation is invisible to onlookers and can substantially stabilise the diseased areas of the brain in the user.

The EASEE® cortical brain stimulation is a pioneering procedure thanks to subcutaneous electrodes positioned outside the skull. The EASEE® system is currently in the clinical trial phase and has not yet been launched.

Good prospects for the future

July 28, 2017

Precisis AG successfully increases capital

Precisis AG is investing in the clinical phase of its product development EASEE®. The medical technology company has increased its share capital to approximately 1.5 million Euros for this purpose. The increase in stock gives it a gross revenue of approximately 3.5 million Euros.
July 3, 2017

Initial tests confirm good tolerance

An initial short-term study performed in an outpatient setting at selected epilepsy centres in Germany shows that the EASEE® stimulation works well and is well-tolerated.
January 3, 2017

Senate of science prizes innovative passion

Dr Angela Liedler, chairwoman and owner of the EASEE® manufacturer Precisis AG was appointed a member of the Senate of Economy in Germany. The community of values brings together solution-driven people from a wide variety of industries.

Individual all your life

EASEE® is a machine learning system, thanks to digital networking. The stimulation parameters can be adjusted to the patient's individual needs, depending on the course of the illness and individual changes.

Dr med. Angela Liedler, CEO of Precisis AG, explains the EASEE® system:

Your life is our inspiration

  • Dr Olga Simova, Epilepsy Centre Hamburg, Ev. Krankenhaus Alsterdorf gGmbH
    "Neuromodulation with electrical stimulation can be a good alternative to epilepsy patients who do not respond to treatment and for whom there is no option to surgically remove the "diseased" part of the brain. This can allow some patients to return to work, to continue their relationships and to get on with their social lives, and so much more. It is definitely worth a try. This is why advances in the stimulation procedures like the EASEE study are important. We have to take any opportunity we can to help a patient."
    Dr Olga Simova, Epilepsy Centre Hamburg, Ev. Krankenhaus Alsterdorf gGmbH
  • Julian, 22, Heidelberg
    "I had my first grand-mal seizure when I was 12. For years after that, I had two to three seizures a day. It was not until 2011 that I was diagnosed with temporal lobe epilepsy. Not a single drug available was able to reduce the seizures, and to boot I also had to cope with side effects like speech disorders and hallucinations. I would have liked a lower risk option aside from brain surgery to treat my epilepsy. But in 2015 this option wasn't available."
    Julian, 22, Heidelberg
  • Britta, 37, Hamburg
    "For 15 years drugs helped me manage my focal epilepsy, but 18 months after the birth of my son, the seizures returned. Since 2015 I have no longer been able to work and am currently in early retirement. The drugs affect my speech and vision and sometimes change my perception; I have gained weight and have more spots than I did in puberty. My liver tests are not good and I am suffering from mild osteoporosis. I have negative experience with mobile vagus nerve stimulation, and I am very worried about the risks associated with deep brain stimulation. I would welcome cortical brain stimulation, and can see myself going for this option."
    Britta, 37, Hamburg